eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Authors
Keywords
-
Journal
NATURE
Volume 513, Issue 7516, Pages 105-109
Publisher
Springer Nature
Online
2014-07-25
DOI
10.1038/nature13572
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex
- (2013) Heather Sadlish et al. ACS Chemical Biology
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Challenging resistance mechanisms to therapies for metastatic melanoma
- (2013) Lucio Tentori et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
- (2012) Y Shao et al. CELL DEATH AND DIFFERENTIATION
- Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors
- (2012) Tao Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- A unifying model for mTORC1-mediated regulation of mRNA translation
- (2012) Carson C. Thoreen et al. NATURE
- The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments
- (2012) Nicholas T Ingolia et al. Nature Protocols
- Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells
- (2011) Sneha V. Gupta et al. AAPS Journal
- The biological and therapeutic relevance of mRNA translation in cancer
- (2011) Sarah P. Blagden et al. Nature Reviews Clinical Oncology
- Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
- (2011) Eftychia Oikonomou et al. PLoS One
- Synthetic Analogue of Rocaglaol Displays a Potent and Selective Cytotoxicity in Cancer Cells: Involvement of Apoptosis Inducing Factor and Caspase-12
- (2009) Frédéric Thuaud et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells
- (2009) Regina Cencic et al. LEUKEMIA RESEARCH
- Identification of direct transcriptional targets ofV600EBRAF/MEK signalling in melanoma
- (2009) Leisl M Packer et al. Pigment Cell & Melanoma Research
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now